Okada, Hiroshi
Tanaka, Muhei
Yasuda, Takashi
Okada, Yuki
Norikae, Hisahiro
Fujita, Tetsuya
Nishi, Takashi
Oyamada, Hirokazu
Yamane, Tetsuro
Fukui, Michiaki
Article History
Received: 19 August 2020
Accepted: 11 January 2021
First Online: 22 January 2021
Competing interests
: Michiaki Fukui received grants from the Japan Society for the Promotion of Science, AstraZeneca Plc, Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Company Ltd., Kissei Pharmaceutical Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Ono Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Co., Ltd., outside the submitted work. The above sponsors were not involved in the study design; collection, analysis, and interpretation of data; writing of this manuscript, or decision to submit the article for publication. The authors, their immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the content of this article. The authors declare that although they are affiliated with a department that is supported financially by a pharmaceutical company, they received no current funding for this study, and this does not alter their adherence to all the journal policies on sharing data and materials. The remaining authors have no conflicts of interest to disclose.